NanoViricides NNVC reports that its
optimized injectable FluCide drug candidate was found to be well
tolerated in a non-GLP small animal safety/toxicology study. This study
is an important step in the drug development pathway for FluCide. This
study will provide guidance for the IND-enabling GLP safety and
toxicology study. The Company previously had a pre-IND meeting with the
U.S. FDA to discuss and receive guidance on the FluCide drug development
pathway. This non-GLP safety and toxicology study was begun in late
September at KARD Scientific in Massachusetts.
Dr. Krishna Menon, VMD, PhD, CEO of KARD Scientific, advised the Company
after the completion of this short study, that mice treated with the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in